The “ No, much better to go straight to a co-commercialisation .....” comment, imo, is spot on, it would be a much better route, from experience with Cardiocell, to go down, ensuring, imo, a far quicker successful ‘take off’
David: In reference to ‘bids’ by potential partners to go the route of ‘co-commercialisation’ do you envisage any specific partner.
Possible obstacle is this: the best possible partner would already be in this field, the dilemma for this company, imo, is would they drop their ‘own’ product to take up the Admedus IP? Bearing in mind the very significant costs in bringing it to market (competitors product).
Alternatively I wonder if Admedus have in mind particularl partners that can bring to the ‘table’ the advantages (ref: sm comment) THAT wish to enter this very lucrative field.
Right of track here: Have always admired the name change from ‘Allied Health’ to ‘Admedus’, sounds lot more classy/distinctive than the former, one non negative reminder of the past .... lol.
- Forums
- ASX - By Stock
- AVR
- Schwarzenegger has valve replacement by catheter.
Schwarzenegger has valve replacement by catheter., page-40
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$13.30 |
Change
0.100(0.76%) |
Mkt cap ! $281.1M |
Open | High | Low | Value | Volume |
$13.23 | $13.30 | $13.01 | $108.9K | 8.321K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50 | $13.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.35 | 107 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50 | 13.010 |
3 | 1013 | 13.000 |
1 | 50 | 12.990 |
1 | 500 | 12.860 |
1 | 778 | 12.850 |
Price($) | Vol. | No. |
---|---|---|
13.350 | 107 | 1 |
13.490 | 2500 | 1 |
13.500 | 3067 | 2 |
14.000 | 1025 | 2 |
14.500 | 1000 | 1 |
Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |